Keyword: Bristol-Myers Squibb
Pfizer’s old dog Sutent has shown it has one more trick to perform as a renal cancer treatment before being passed up by the new breed of I-O drugs.
In just a few years, pharma's top launches of 2014 have amassed huge sales and reshaped treatment—and they're now among the biggest launches ever.
Outcome Health investors sued for fraud Tuesday, weeks after whistleblower allegations threw the company into turmoil.
Now that Opdivo has posted 2017 growth, all eyes are on what the drug can pull off next year. And kidney cancer will factor in heavily.
With Opdivo's third straight sales beat of the year in the books, the company has laid investors' 2017 growth worries to rest.
Johnson & Johnson has successfully challenged two talc verdicts and wiped away nearly $500 million in liabilities.
Here’s a sentence Bristol-Myers Squibb should be used to by now: England’s cost watchdogs have decided not to back routine NHS coverage of Opdivo.
Bristol-Myers aims to get its I-O med Opdivo to cancer patients as early as possible, and a new approval in melanoma would be a step in that direction.
J&J has escaped a $72 million verdict in its ongoing talcum powder saga, the first reversal of its numerous losses.
In the wake of Hurricane Maria, J&J says the company's Puerto Rico manufacturing plants "fared well," but "intermittent" shortages could follow.